Imatinib for Multiple Sclerosis (MS) Relapses

Phase 2 Unknown 200 enrolled Tomas Olsson The Swedish Research Council · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

To investigate if treatment with Imatinib results in a better outcome than standard care in form of Methylprednisolone(MP) after MS-associated relapses.

Timeline

Start: 2018-10-01
Primary completion: 2022-12-31
Completion: 2023-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	Oral
Comparator	Methylprednisolone	Other / unclassified	1 g	Oral

Imatinib for Multiple Sclerosis (MS) Relapses

Summary

Timeline

Drugs

Indications